Literature DB >> 9450554

The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction.

G Høyer-Hansen1, N Behrendt, M Ploug, K Danø, K T Preissner.   

Abstract

The urokinase receptor (uPAR) is a receptor for both urokinase plasminogen activator (uPA) and the adhesion protein vitronectin. There are two forms of cell surface-bound uPAR; intact uPAR and a cleaved form, uPAR(2+3), which is formed by uPA-catalyzed cleavage of uPAR. In ligand-blotting experiments we found that vitronectin binds uPAR but not uPAR(2+3). In real-time biomolecular interaction analysis using recombinant, soluble uPAR (suPAR) both plasma and multimeric forms of vitronectin bound to intact, antibody-immobilized suPAR. Monoclonal antibodies against domain 1 of uPAR blocked suPAR binding to vitronectin and vitronectin did not interact with suPAR(2+3). Both suPAR(2+3) and the isolated domain 1 failed to compete with the intact suPAR in binding to vitronectin. We therefore conclude that the intact receptor is required for efficient vitronectin binding.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9450554     DOI: 10.1016/s0014-5793(97)01491-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  27 in total

1.  Isolation and characterization of cell lines with reduced urokinase binding.

Authors:  H K Lau; J M Teitel; M Kim
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance.

Authors:  Evelyn C Nieves; Naveen Manchanda
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

3.  Structural basis of interaction between urokinase-type plasminogen activator and its receptor.

Authors:  Cyril Barinka; Graham Parry; Jennifer Callahan; David E Shaw; Alice Kuo; Khalil Bdeir; Douglas B Cines; Andrew Mazar; Jacek Lubkowski
Journal:  J Mol Biol       Date:  2006-08-26       Impact factor: 5.469

4.  Urokinase receptor cleavage: a crucial step in fibroblast-to-myofibroblast differentiation.

Authors:  Audrey M Bernstein; Sally S Twining; Debra J Warejcka; Edward Tall; Sandra K Masur
Journal:  Mol Biol Cell       Date:  2007-05-16       Impact factor: 4.138

Review 5.  Regulation of cell signalling by uPAR.

Authors:  Harvey W Smith; Chris J Marshall
Journal:  Nat Rev Mol Cell Biol       Date:  2010-01       Impact factor: 94.444

6.  Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice.

Authors:  Dominique Cathelin; Sandrine Placier; Michael Ploug; Marie-Christine Verpont; Sophie Vandermeersch; Yosu Luque; Alexandre Hertig; Eric Rondeau; Laurent Mesnard
Journal:  J Am Soc Nephrol       Date:  2014-05-01       Impact factor: 10.121

Review 7.  VEGF-initiated angiogenesis and the uPA/uPAR system.

Authors:  Johannes M Breuss; Pavel Uhrin
Journal:  Cell Adh Migr       Date:  2012-10-17       Impact factor: 3.405

8.  Increased levels of urokinase plasminogen activator receptor in prostate cancer cells derived from repeated metastasis.

Authors:  Katie Forbes; Karin Gillette; Laura A Kelley; Inder Sehgal
Journal:  World J Urol       Date:  2004-03-30       Impact factor: 4.226

9.  A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor.

Authors:  Thore Hillig; Lars H Engelholm; Signe Ingvarsen; Daniel H Madsen; Henrik Gårdsvoll; Jørgen K Larsen; Michael Ploug; Keld Danø; Lars Kjøller; Niels Behrendt
Journal:  J Biol Chem       Date:  2008-03-24       Impact factor: 5.157

10.  Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.

Authors:  A F Lomholt; G Høyer-Hansen; H J Nielsen; I J Christensen
Journal:  Br J Cancer       Date:  2009-08-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.